BAKER BROS ADVISORS LLC Insider Trading $BGNE BeiGene, Ltd.
Get free email notifications about insider trading for BAKER BROS ADVISORS LLC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BAKER BROS ADVISORS LLC. BAKER BROS ADVISORS LLC is 10% Owner in BIOCRYST PHARMACEUTICALS INC ($BCRX) and Director in INCYTE CORP ($INCY) and Director in ALEXION PHARMACEUTICALS INC ($ALXN) and 10% Owner in IDERA PHARMACEUTICALS, INC. ($IDRA) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in XOMA Corp ($XOMA) and Director in ACADIA PHARMACEUTICALS INC ($ACAD) and Director in SEATTLE GENETICS INC /WA ($SGEN) and Director in GENOMIC HEALTH INC ($GHDX) and 10% Owner in BELLICUM PHARMACEUTICALS, INC ($BLCM) and 10% Owner in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in AQUINOX PHARMACEUTICALS, INC ($AQXP) and Director in Zymeworks Inc. ($ZYME) and Director in Kodiak Sciences Inc. ($KOD) and 10% Owner in Invitae Corp ($NVTA) and Director in IGM Biosciences, Inc. ($IGMS) and 10% Owner in Atreca, Inc. ($BCEL) and in Mirati Therapeutics, Inc. ($MYG) and 10% Owner in Mirati Therapeutics, Inc. ($MYG) and Director in Talis Biomedical Corp ($TLIS) and Director in Aeglea BioTherapeutics, Inc. ($AGLE) and in RHYTHM PHARMACEUTICALS, INC. ($RYTM) and in Intellia Therapeutics, Inc. ($NTLA) and Director in BeiGene, Ltd. ($BGNE) and Director in Prelude Therapeutics Inc ($PRLD) and Director in Kiniksa Pharmaceuticals, Ltd. ($KNSA) and in HOOKIPA Pharma Inc. ($HOOK).
BAKER BROS ADVISORS LLC in BeiGene, Ltd.
Trading Symbol: BGNEIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of BAKER BROS ADVISORS LLC: Director
Holdings: 10,418 shares
Current Value: $374,215
Latest Transaction: Dec 04 2020
$BGNE Market Capitalization: $1.14B
$BGNE Previous Close: $35.92
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of BAKER BROS ADVISORS LLC in BeiGene, Ltd.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACAD, AGLE, ALXN, BCEL, BGNE, BLCM, BCRX, GHDX, HOOK, IDRA, IGMS, INCY, NTLA, NVTA, KNSA, KOD, MYG, NLTX, PRLD, RYTM, SGEN, TLIS, XOMA, ZYME
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 1,386,033 | 305,620,277 | 10,811,048 | 12.2 M to 10.8 M (-11.36 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | S | 220.50 | 125,513 | 27,675,617 | 979,003 | 1.1 M to 979 K (-11.36 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
Dec 04 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Gift | G | 0.00 | 13,516 | 0 | 10,418 | 23.9 K to 10.4 K (-56.47 %) |
Jul 17 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 14.23 | 13,589,904 | 193,395,206 | 18,840,379 | 5.3 M to 18.8 M (+258.83 %) |
Jul 17 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 14.23 | 994,276 | 14,149,343 | 1,021,851 | 27.6 K to 1 M (+3,605.72 %) |
Jun 19 2020 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 13.42 | 90,766 | 1,218,080 | 90,766 | |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 9.23 | 129,220 | 1,192,701 | 129,220 | |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 43,109 | 0 | 43,109 | 0 to 43.1 K |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 43,109 | 0 | 43,109 | 0 to 43.1 K |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 582,200 | 0 | 18,591 | 600.8 K to 18.6 K (-96.91 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 13,516 | 0 | 20,618 | 7.1 K to 20.6 K (+190.31 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 13,516 | 0 | 20,618 | 7.1 K to 20.6 K (+190.31 %) |
Jun 07 2019 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 182,539 | 0 | 1,028,034 | 1.2 M to 1 M (-15.08 %) |
Aug 06 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 108.00 | 5,231,900 | 565,045,200 | 5,250,491 | 18.6 K to 5.3 M (+28,142.11 %) |
Aug 06 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 108.00 | 582,200 | 62,877,600 | 600,791 | 18.6 K to 600.8 K (+3,131.62 %) |
Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 16.15 | 34,884 | 563,377 | 34,884 | |
Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 18,580 | 0 | 73,180,602 | 73.2 M to 73.2 M (+0.03 %) |
Jun 08 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 18,580 | 0 | 6,551,715 | 6.5 M to 6.6 M (+0.28 %) |
Jan 22 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 101.00 | 1,645,148 | 166,159,948 | 5,121,404 | 3.5 M to 5.1 M (+47.33 %) |
Jan 22 2018 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 101.00 | 335,050 | 33,840,050 | 708,025 | 373 K to 708 K (+89.83 %) |
Oct 16 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 7,102 | 0 | 7,102 | 0 to 7.1 K |
Oct 16 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | J | 0.00 | 7,102 | 0 | 7,102 | 0 to 7.1 K |
Oct 16 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Sell | J | 0.00 | 49,200 | 0 | 0 | 49.2 K to 0 (-100.00 %) |
Aug 14 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 71.00 | 158,279 | 11,237,809 | 3,476,256 | 3.3 M to 3.5 M (+4.77 %) |
Aug 14 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 71.00 | 17,777 | 1,262,167 | 372,975 | 355.2 K to 373 K (+5.00 %) |
Apr 21 2017 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | A | 2.84 | 399,984 | 1,135,955 | 399,984 | |
Nov 21 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.00 | 1,594,671 | 51,029,472 | 3,317,977 | 1.7 M to 3.3 M (+92.54 %) |
Nov 21 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 32.00 | 165,824 | 5,306,368 | 355,198 | 189.4 K to 355.2 K (+87.56 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 56,853 | 38,376 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 2,296,890 | 1,550,401 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | X | 0.68 | 238,850 | 161,224 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 26,292,961 | 0 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 1,912,167 | 0 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 582,747 | 0 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 44,572,171 | 0 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Option Exercise | C | 0.00 | 4,382,118 | 0 | 0 | |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 24.00 | 1,723,306 | 41,359,344 | 1,723,306 | 0 to 1.7 M |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | P | 24.00 | 189,374 | 4,544,976 | 189,374 | 0 to 189.4 K |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 56,853 | 38,376 | 639,600 | 582.7 K to 639.6 K (+9.76 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 2,296,890 | 1,550,401 | 73,162,022 | 70.9 M to 73.2 M (+3.24 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | X | 0.68 | 238,850 | 161,224 | 6,533,135 | 6.3 M to 6.5 M (+3.79 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 26,292,961 | 0 | 70,865,132 | 44.6 M to 70.9 M (+58.99 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 1,912,167 | 0 | 6,294,285 | 4.4 M to 6.3 M (+43.64 %) |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 582,747 | 0 | 582,747 | 0 to 582.7 K |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 44,572,171 | 0 | 44,572,171 | 0 to 44.6 M |
Feb 09 2016 | BGNE | BeiGene, Ltd. | BAKER BROS. ADVISORS LP | Director | Buy | C | 0.00 | 4,382,118 | 0 | 4,382,118 | 0 to 4.4 M |
Page: 1